Navigation Links
Medivation Announces Presentation of Positive MDV3100 Clinical Data in Castration-Resistant Prostate Cancer Patients at 44th ASCO Annual Meeting
Date:6/2/2008

- Observed Dose-Response Trends Suggest Improved Efficacy with Higher Doses

-

- Dose Escalation Ongoing -

SAN FRANCISCO and CHICAGO, June 2 /PRNewswire-FirstCall/ -- Medivation, Inc. (Nasdaq: MDVN) today announced that data from an ongoing Phase 1-2 clinical trial of the Company's novel androgen receptor antagonist, MDV3100, showed encouraging anti-tumor activity as measured by declining serum levels of prostate specific antigen (PSA) and circulating tumor cells (CTC), as well as radiographic disease stabilization, after three months of treatment. An increased number of androgen receptors present on prostate cancer cells is believed to play a major role in the growth of castration-resistant prostate cancer, also known as hormone-refractory prostate cancer. The observed clinical effects of MDV3100 on PSA levels, CTC counts and radiographic disease are consistent with blockade of androgen receptor signaling and inhibition of tumor growth. To date, 90 patients have been enrolled in the trial with enrollment completed at doses up to 240 mg/day. MDV3100 has been well tolerated and dose escalation at 360 mg/day is in progress.

The data were presented at the American Society of Clinical Oncology 2008 Annual Meeting in Chicago in an oral presentation entitled "Phase 1-2 study of MDV3100 in patients (pts) with progressive Castration-Resistant Prostate Cancer (CRPC)" by principal investigator, Howard Scher, M.D., chief of the Genitourinary Oncology Service and the D. Wayne Calloway Chair in Urologic Oncology at Memorial Sloan-Kettering Cancer Center in New York.

The ongoing Phase 1-2 trial is an open-label U.S. dose-escalation study enrolling prostate cancer patients
'/>"/>

SOURCE Medivation, Inc.
Copyright©2008 PR Newswire.
All rights reserved

2

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Medivation Announces Presentation of MDV3100 Clinical Data in Patients With Castration-Resistant Prostate Cancer at 44th American Society of Clinical Oncology Annual Meeting
2. Medivations Dimebon(TM) Significantly Improved Thinking and Memory in Alzheimers Disease Patients Over One Year
3. Medivations Dimebon(TM) Significantly Improved Daily Function in Alzheimers Disease Patients, Resulting in Reduced Need for Caregiver Assistance
4. Medivations Dimebon(TM) Stabilizes Behavioral Symptoms in Alzheimers Disease Patients, Resulting in Reduced Caregiver Distress
5. Medivations MDV3100 Demonstrates Substantial PSA Reductions in First Patient Groups Treated in Phase 1-2 Hormone Refractory Prostate Cancer Trial
6. Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois
7. IDM Pharma Announces Phase 2 Follow-Up Data Showing IDM-2101 is Well Tolerated With Positive Survival Trend in Non-Small Cell Lung Cancer Patients
8. Nektar Announces Expanded Phase 2 Clinical Development Plan For NKTR-102 (PEG-irinotecan)
9. CuraGen Announces Data From Ongoing Phase I/II Trial Showing Clinical Activity of CR011-vcMMAE in Metastatic Melanoma
10. Poniard Announces Positive Efficacy and Safety Data From Phase 1 Trial of Picoplatin in Multiple Tumor Types Including Ovarian Cancer
11. Poniard Announces Positive Preliminary Efficacy and Safety Data From Ongoing Phase 2 Trial of Picoplatin in First-Line Treatment of Colorectal Cancer

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/9/2009)...ov. 9 Access MediQuip, LLC, the na...plantable medical device management solutions to t... relocating its corporate headquarters to Lake Mar...inued rapid growth, includes a major expansion of ... open in January 2010 and relocation and expansion...
(Date:11/9/2009).... 9 RBC Life Sciences,...proprietary nutritional supplements and wound care...he Top 100 workplaces in the Dallas-Fort Worth are...he Top 100 Places to Work 2009 competition surveye... medium and large firms throughout the DFW metropo...
(Date:11/9/2009)... 9 Arcadia Resources, In...ative consumer health care services under the Arca...ldsmith to its Board of Directors. Goldsmith will...rom the Board. ,, (Photo: http://www.newsc...dsmith is the Daniel Paul Professor of Government ...
Breaking Medicine Technology:Access MediQuip Moves Company Headquarters to Lake Mary, Florida 2RBC Life Sciences Ranked as One of the Top 100 Workplaces in the Dallas-Fort Worth Area 2Arcadia Resources Names Stephen Goldsmith to Board of Directors 2Arcadia Resources Names Stephen Goldsmith to Board of Directors 3Minorities have poorer results higher rates of inappropriate surgery to prevent stroke 55308 1Minorities have poorer results higher rates of inappropriate surgery to prevent stroke 55308 2Nottingham scientists commissioned for urgent swine flu research 55306 1Nottingham scientists commissioned for urgent swine flu research 55306 2New study suggests the brain predicts what eyes in motion will see 55304 1New study suggests the brain predicts what eyes in motion will see 55304 2
...(BUSINESS WIRE)--Apr 30, 2007 - Insmed Inc.,(Nasd...hase II,investigator-sponsored clinical study of t...ts affected with HIV-associated,Adipose Redistribu...e study, being conducted at the,University of Cali... 0.5 mg/kg/day IPLEX treatment in seven patients i...
...Y, England, April 30, 2007 /PRNewswire-FirstCall/,...reading to the,lungs, the brain or the bone which ...lised to the breast , Newly published data in the ... Press show that after two years of post-surgical,...ve early breast,cancer treated with Femara experie...
Other Medicine Technology:Insmed Releases Positive Results from Iplex Phase II HIV-Associated,Adipose Redistribution Syndrome Clinical Study 2Insmed Releases Positive Results from Iplex Phase II HIV-Associated,Adipose Redistribution Syndrome Clinical Study 3Insmed Releases Positive Results from Iplex Phase II HIV-Associated,Adipose Redistribution Syndrome Clinical Study 4Newly Published Study Reveals Femara Improves Chances for Harder to,Treat Early Breast Cancer Relapse in Postmenopausal Women 2Newly Published Study Reveals Femara Improves Chances for Harder to,Treat Early Breast Cancer Relapse in Postmenopausal Women 3Newly Published Study Reveals Femara Improves Chances for Harder to,Treat Early Breast Cancer Relapse in Postmenopausal Women 4Newly Published Study Reveals Femara Improves Chances for Harder to,Treat Early Breast Cancer Relapse in Postmenopausal Women 5
(Date:11/10/2009)... It is now possible to achieve exceptionally s...sed of hard materials such as ceramics, carbide an...h the new Diamond Flex-Hone® honing tool fro... Los Angeles (PRWEB) November 10, 2009 -- Usi...edded to the ends of flexible filaments, the Diamo...
(Date:11/10/2009)... Carrington Nuamah, P.C., a Seattle law firm p... and estate law, has unveiled a new website. Resi...learn more about the firm at www.carringtonnuamah...is Nexis) November 10, 2009 -- Seattle Law Firm Ca...t www.carringtonnuamah.com . Lawyers Andrew Carr...
(Date:11/10/2009)...ersity Rollins School of Public Health researchers...American Public Health Association,s annual meetin... compliance with national recommendations that a p...tes of their arrival to the Emergency Department (...s from Emory scientists are highlighted below. , ...
(Date:11/9/2009)... Tarkett Sports, the worldwide leader in sport...oduct offering with a more complete and innovative...ndoor sports flooring experts and the launch of w... (PRWEB) November 9, 2009 -- Tarkett Sports, ...ooring products includes hardwood and synthetic ba...
(Date:11/9/2009)... on Election Promise. Now Is Time for Senate to Ac.../ -- The following is a statement by Anna Burger, ...truggle and decades of delay, the U.S. House of Re...ss historic reform legislation to assure every Ame... quality, affordable health care. The House,s acti...
Breaking Medicine News(10 mins):Health News:Diamond Honing Tool Technology: The New Standard in Surface Finishing of Hard Materials 2Health News:Seattle Law Firm Carrington Nuamah Launches New Website for Personal Injury, Bankruptcy, Immigration and Estate Law 2Health News:Some chest pain patients wait longer than 10 minutes to see ER physician 2Health News:Tarkett Sports Launches Revamped Indoor Sports Flooring Division and New Indoor Website 2Health News:Statement of Anna Burger, Chair, Change to Win, on U.S. House Vote for Health Care Reform 2
..., VA Researchers have developed a series of tests...rmality of taste (gustatory function) and smell (o... a new study published in the July 2008 edition of...ority of 16 different test odorants that can measu...
...eive Grants as 4th & 5th Graders ,Walked the Walk ...dhood Obesity Campaign, - Campaign Addresses Futu... Children Are Obese, ORANG...essful participation in the Sixth,Annual KID HEALT...
...nce in the Dallas-Fort Worth market, NORTH HOLLYW... Inc. (Nasdaq: IPCM ), a leading national physici... has acquired Texas,Inpatient Services (T.I.P.S.)....ion of,T.I.P.S. continues to strengthen IPC,s posi...
..., June 30 Smart Balance, Inc.,(Nasdaq: SMBL ) an...ad-market Russell 2000(R) and Russell 3000(R) inde...ensive set of U.S. and global equity,indexes on Ju...investors," said Robert S. Gluck, Vice Chairman an...
...tion seeks policy, social changes that boost healt... (HealthDay News) -- Reducing the high rate of obe..., population-based strategy, says a new American H...ng right and being physically active. , About 67 m...
...t liver transplantation reliably yield grafts for ...de new findings about the procedure in the July is...Wiley & Sons. The articles are also available onli...ties for those in need of a transplant. An example...
Other Medicine News:Health News:So. Calif. Schools Receive $14,500 From KID HEALTHY -- Steps To Healthy Living Campaign! 2Health News:So. Calif. Schools Receive $14,500 From KID HEALTHY -- Steps To Healthy Living Campaign! 3Health News:IPC The Hospitalist Company Acquires Texas Inpatient Services 2Health News:Smart Balance Added to Russell 2000 and 3000 Indexes 2Health News:Population-Based Strategy Urged to Cut U.S. Obesity Rate 2Health News:Experts examine challenges of split liver transplantation 2
SLM 4000 Autolensmeter
CL-100 4.0 Computerized Lensmeter
Pro-lll
FF 450plus Iru
Medicine Products: